Literature DB >> 35125738

Prenatal Invasive Testing at a Tertiary Referral Center in India: A Report of 433 Cases Under a Single Operator.

Vandana Bansal1,2, Rujul Jhaveri3.   

Abstract

PURPOSE OF THE STUDY: Chromosomal aneuploidies are major causes of perinatal death and childhood handicap. Awareness about screening and prenatal diagnosis for these disorders among obstetricians and primary care physicians is increasing. Since invasive tests like amniocentesis or chorionic villus sampling (CVS) are associated with a risk of miscarriage these tests should be carried out judiciously in pregnancies considered to be at high risk for aneuploidies and other genetic disorders. The purpose of our study was to examine the patterns, trends and outcomes of the various screening procedures and invasive tests results.
METHODOLOGY: Retrospective observational study done over a period of 3 years and one month including 433 pregnant women with high risk for genetic disorders undergoing invasive prenatal testing like chorionic villus sampling, amniocentesis or cordocentesis. Data were collected from our department records regarding the maternal age, indication for invasive testing, past obstetric history, family history of genetic syndromes, ultrasound findings in the current sonographic examination and the results of the tests done. Any immediate or late complications of the procedure if any were telephonically addressed.
RESULTS: A total of 436 procedures on 433 patients (418 singleton,12 single fetus of twin, 3 both fetuses of twins) were done out of which 281 were amniocentesis(64.4%), 153 were chorionic villus sampling (35.1%) and 2 were cordocentesis(< 1%). Of the 436 procedures, 373(85.5%) were done for positive screening tests for chromosomal aneuploidies and 63(14.4%) were done for previous history of genetic syndromes. The positive predictive value of biochemical marker alone was around 2.7% and higher around 13% for a combined first trimester or a second-trimester screen along with ultrasound abnormalities. The higher the biochemical risk does not translate into higher chance of chromosomal abnormality. Nineteen percentage of fetuses with NT above 95th centile had chromosomal abnormality. Twenty-one percentage of fetuses with absent nasal bone in our study had trisomy 21.
CONCLUSION: Aneuploidy screening is the most common indication for prenatal invasive testing with dual marker combined with nuchal translucency, nasal bone, tricuspid regurgitation and ductus venosus flow providing the best detection rates. The chance of an affected fetus in a patient with aneuploidy screen positive overall is only 6.7%. © Federation of Obstetric & Gynecological Societies of India 2021.

Entities:  

Keywords:  Amniocentesis; Aneuploidy; Chorionic villus sampling; Invasive tests; Prenatal test

Year:  2021        PMID: 35125738      PMCID: PMC8804047          DOI: 10.1007/s13224-021-01496-9

Source DB:  PubMed          Journal:  J Obstet Gynaecol India        ISSN: 0975-6434


  14 in total

1.  International, collaborative assessment of 146,000 prenatal karyotypes: expected limitations if only chromosome-specific probes and fluorescent in-situ hybridization are used.

Authors:  M I Evans; G P Henry; W A Miller; T H Bui; R J Snidjers; R J Wapner; P Miny; M P Johnson; D Peakman; A Johnson; K Nicolaides; W Holzgreve; S A Ebrahim; R Babu; L Jackson
Journal:  Hum Reprod       Date:  1999-05       Impact factor: 6.918

2.  First and second trimester antenatal screening for Down's syndrome: the results of the Serum, Urine and Ultrasound Screening Study (SURUSS).

Authors:  N J Wald; C Rodeck; A K Hackshaw; J Walters; L Chitty; A M Mackinson
Journal:  Health Technol Assess       Date:  2003       Impact factor: 4.014

3.  Trends in state/population-based Down syndrome screening and invasive prenatal testing with the introduction of first-trimester combined Down syndrome screening, South Australia, 1995-2005.

Authors:  Peter R Muller; Robert Cocciolone; Eric A Haan; Chris Wilkinson; Heather Scott; Leonie Sage; Renata Bird; Rhonda Hutchinson; Annabelle Chan
Journal:  Am J Obstet Gynecol       Date:  2007-04       Impact factor: 8.661

Review 4.  Procedure-related risk of miscarriage following amniocentesis and chorionic villus sampling: a systematic review and meta-analysis.

Authors:  R Akolekar; J Beta; G Picciarelli; C Ogilvie; F D'Antonio
Journal:  Ultrasound Obstet Gynecol       Date:  2015-01       Impact factor: 7.299

5.  ISUOG Practice Guidelines: invasive procedures for prenatal diagnosis.

Authors:  T Ghi; A Sotiriadis; P Calda; F Da Silva Costa; N Raine-Fenning; Z Alfirevic; G McGillivray
Journal:  Ultrasound Obstet Gynecol       Date:  2016-08       Impact factor: 7.299

6.  First-trimester or second-trimester screening, or both, for Down's syndrome.

Authors:  Fergal D Malone; Jacob A Canick; Robert H Ball; David A Nyberg; Christine H Comstock; Radek Bukowski; Richard L Berkowitz; Susan J Gross; Lorraine Dugoff; Sabrina D Craigo; Ilan E Timor-Tritsch; Stephen R Carr; Honor M Wolfe; Kimberly Dukes; Diana W Bianchi; Alicja R Rudnicka; Allan K Hackshaw; Geralyn Lambert-Messerlian; Nicholas J Wald; Mary E D'Alton
Journal:  N Engl J Med       Date:  2005-11-10       Impact factor: 91.245

7.  Study of stillbirth and major congenital anomaly among newborns in the high-level natural radiation areas of Kerala, India.

Authors:  G Jaikrishan; K R Sudheer; V J Andrews; P K M Koya; M Madhusoodhanan; C K Jagadeesan; M Seshadri
Journal:  J Community Genet       Date:  2012-08-09

8.  First-trimester combined ultrasound and biochemical screening for Down syndrome in routine clinical practice.

Authors:  E J Stenhouse; J A Crossley; D A Aitken; K Brogan; A D Cameron; J M Connor
Journal:  Prenat Diagn       Date:  2004-10       Impact factor: 3.050

9.  Mid-second Trimester Measurement of Nasal Bone Length in the Indian Population.

Authors:  Bandeppa H Narayani; Prathima Radhakrishnan
Journal:  J Obstet Gynaecol India       Date:  2013-02-22

10.  Is there still a role for nuchal translucency measurement in the changing paradigm of first trimester screening?

Authors:  Francesca Bardi; Pien Bosschieter; Joke Verheij; Attie Go; Monique Haak; Mireille Bekker; Esther Sikkel; Audrey Coumans; Eva Pajkrt; Caterina Bilardo
Journal:  Prenat Diagn       Date:  2019-11-27       Impact factor: 3.050

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.